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 Recent advances and perspectives in the synthesis of bioactive coumarins 
E. Calcio Gaudinoa, S. Tagliapietraa, K. Martinaa, G. Palmisanob, G. Cravotto *a  
 
The impressive pharmacological properties shown 
by a number of coumarins have lead to 
extraordinarily large emphasis being placed on the 
design of more efficient and greener synthetic 
procedures to produce them. The increasing use of 
enabling technologies, such as microwaves, 
ultrasound, new heterogeneous catalysts and 
greener solvents in recent years has made access to 
coumarin derivatives much simpler. This review will 
highlight the most recent synthetic advances that 
make use of non-conventional methods and energy 
sources and some perspectives for the future. 
1 Introduction 
Naturally occurring coumarins and their synthetic derivatives 
are well known for their significant biological and 
pharmacological properties, which include anticoagulant, 
antimicrobial, antitumor, anti-HIV, anti-inflammatory and 
antioxidant activities.1 Coumarins have found widespread 
applications in several fields,2-8 including drugs, cosmetics, 
pesticides and fluorescent dyes,9 to such an extent that not 
even a book, never mind a review, would be sufficient to 
describe them completely. The impressive molecular diversity 
found in coumarins has lead to a number of excellent surveys 
according to chemical structure,10 such as 
prenyloxycoumarins,11 furocoumarins12 and 
hydroxycoumarins.13 Recent reviews have highlighted the 
progress of coumarin derivatives in drug development. 
Examples include antioxidant,14,15 anticoagulant,16 
anticancer,17-20 antituberculosis21 and anti-inflammatory 
agents.22,23 The coumarin skeleton is at the core of important 
antibiotics, such as novobiocin, coumermycin A1 and 
chlorobiocin,24 and remains a valuable source of lead 
compounds for the design and development of effective 
antimicrobial and antifungal therapy drugs.25 
Coumarin derivatives are usually prepared via the chemical 
modification of the benzopyran ring. Classic coumarin 
preparation makes use of the von Pechmann,26 Perkin, 
Knoevenagel,27 Reformatski, Kostanecki-Robinson, Wittig and 
Baylis-Hillman reactions as well as the Baker-Venkataraman 
rearrangement and the intramolecular Claisen condensation. 
Most synthetic procedures are costly, time consuming, not 
environmentally friendly, give relatively poor yields,  
 
incompatible with other functional groups and require 
laborious purification. However, the last two decades have seen 
new, efficient and green methods that use non-conventional 
energy sources, such as microwaves (MW)28 and ultrasound 
irradiation,29 being developed.30, 31 
In this work, we present an overview of recent literature and 
technical advances in this research field in order to provide 
insight into modern approaches to the synthesis of bioactive 
coumarins. 
The review is made up of four main paragraphs which are 
subdivided according to coumarin structure and 
functionalization: 1) simple coumarins, 2) pyranocoumarins, 3) 
furocoumarins and 4) hybrid coumarin derivatives. This review 
covers the literature from January 2013 to the end of 2015. 
Earlier papers that are nonetheless relevant and had not 
previously been reviewed are cited in some cases. 
 
1.1. Simple coumarins 
Multi-functionalized coumarins bare at least two substituents 
with different functional groups.32 Several efficient synthetic 
procedures for these have recently been reported in the 
literature.  Vahabi et al. (2014),33 have described a rapid 
solvent-free, one-pot synthesis of coumarin derivatives via the 
von Pechmann condensation of phenols with ethyl 
acetoacetate using FeF3 as an acid catalyst under MW 
irradiation (Scheme 1). The best results were obtained in 
solvent-free conditions at 110 °C (MW power 450 W) and 1 bar 
(95% yield). The same reaction entailed longer reaction times 
and gave lower yields when carried out in solution 
(dimetylformamide, acetonitrile, dioxane, water). The 
antimicrobial and antifungal activity of all products was 
screened (Staphylococcus aureus, Escherichia coli, Aspergillus 
niger and Helminthosporium oryzae) using penicillin and 
griseofulvin as standard reference drugs. Good activity against 
both bacteria and fungi was found in all compounds, but 
especially in (a), (b), (c) and (d) (Scheme 1). 
 
 
Scheme 1. FeF3 catalyzed von Pechmann reaction. 
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Chandramouli et al. (2013),34 have reported the synthesis of 
coumarin derivatives in the presence of catalytic amounts of 
urotropine in ionic liquids (i.e. [BMIM]BF4 and [BIPIM]BF4). The 
Baylis-Hillman reaction gave good yields under MW irradiation 
(76-84% yields) (Scheme 2). The antibacterial activity of all 
compounds (Bacillus subtilis, Bacillus sp., Pseudomonas putida 
and E. coli) proved to be moderate compared to streptomycin. 
 
 
Scheme 2. Synthesis of Baylis-Hillman adducts. 
Microbial biotransformation has also been used for these 
synthetic aims. Nigam et al. (2013),35 have described a new 
microbial transformation of the benzopyran ring system via the 
functional group transferring action of various fungi and 
bacteria (Scheme 3). The O-deethylation of 7-ethoxy-4-
methylcoumarin by Streptomyces griseus and O-methylation to 
the 7-methoxy analogue by Candida tropicalis occurred in very 
poor yields (4.2% after 72 h and 5.5% after 5 d, respectively). 
Although conversion and purification still require considerable 
improvement, 7-hydroxy-4-methylcoumarin showed 
interesting inhibitory activity (B. subtilis, S. aureus, E. coli and P. 
aeruginosa). 
 
 
Scheme 3. Microbial biotransformation of coumarin ring system. 
Four chalcone-triclosan, chromone-triclosan and coumarin-
triclosan hybrid compounds have been synthesized by Otero et 
al. (2014),36 and tested for their cytotoxic and leishmanicidal 
activities. Initially, 7-hydroxy-4-methylcoumarin (obtained from 
the MW- assisted von Pechmann reaction between resorcinol 
and ethyl acetoacetate) was alkylated with 1,ω-dibromoalkanes 
(ω = 3, 4, 5, 8) in the presence of  KOH, which gave the 
respective bromoalkyl derivatives in significantly rapid times. 
These compounds were then coupled with triclosan to produce 
the corresponding coumarin hybrids in 50–80% yields (Scheme 
4). All compounds showed higher leishmanicidal activity than 
cytotoxicity. This high leishmanicidal activity and low 
cytotoxicity meant that these compounds were found to be 
promising candidates as drug development templates. SAR 
studies had previously established that a short chain improves 
selectivity. 
 
 
Scheme 4. Synthetic pathway for triclosan-coumarins. 
The orphan G-protein-coupled receptor, GPR55, which is 
activated by 1-lysophosphatidylinositol and interacts with 
cannabinoid (CB) receptor ligands, has been proposed as a new 
potential drug target for the treatment of diabetes, Parkinson’s 
disease, neuropathic pain and cancer. The development of 
coumarin derivatives as novel ligands for CB (cannabinoid) 
receptors has recently been reported.37 The properties of 7-
alkyl-3-benzylcoumarins have been compared with those of 
GPR55 antagonists (G-protein-coupled receptor), Δ9-
tetrahydrocannabivarin (a), and cannabidivarin (b), a 
cannabidiol analogue, which were isolated from Cannabis 
sativa, and are depicted in Figure 1. 
 
 
Figure 1. Structural comparison of cannabinoid receptor antagonists (PSB-CS-1201) and 
agonist (PSB-CS-1202, PSB-CS-1204) with the GPR55 antagonists ∆9-
tetrahydrocannabivarin (a) and cannabidivarin (b). 
Müller et al. (2013),37 have established a straightforward 
coumarin synthesis for these derivatives; a one-pot procedure 
from suitably substituted salicylaldehydes and α,β-unsaturated 
aldehydes under MW irradiation (110 °C for 50 min, 200 W). 
Selective and competitive GPR55 antagonists were identified 
among the 7-unsubstituted coumarins produced. These include 
3-(2-hydroxybenzyl)-5-isopropyl-8-methyl-2H-chromen-2-one 
(a), that has derivatives with long alkyl chains in the 7 position 
which are potent, possibly allosteric, GPR55 antagonists with 
ancillary CB receptor affinity (b) (Scheme 5). 
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Scheme 5. Coumarin GPR55 antagonist (a) and allosteric antagonist (b). 
Chen et al. (2013),38 have designed and synthesized novel 
diphenylethylene–coumarin derivatives, containing varying 
numbers of amino side chains, in good yields under MW 
radiation. 3,4-Diphenyl coumarins were synthesized by reacting 
resorcinol with 4-hydroxybenzoic acid to yield benzophenone 
under Fries reaction conditions. The treatment of 
benzophenone with phenyl acetic acid mainly gave the acylated 
3,4-diaryl coumarin derivative via the Perkin reaction route. The 
acetyl groups of these compounds were removed in acidic 
solution and provided free phenol –OH, whose derivatization 
with 1,2-dibromoethane yielded the mono- and di-O-alkyl 
bromo derivatives. The SN2 substitution of bromine with a 
variety of amines provided the final products which either 
contained two amino alkyl chains or one side chain at the 7-
position (Scheme 6). The triaminoalkyl derivatives were 
obtained in the same way from the corresponding 3-
methossiphenol. MW irradiation efficiently improved the Perkin 
reaction and nucleophilic substitution. Of those prepared and 
tested, four compounds containing two amino alkyl chains [(a): 
R = morpholinyl, (b): R = pyrrolidinyl, (c): R = piperidinyl, (d): R = 
NEt2] proved themselves to possess superior anti-proliferative 
activity to the positive controls against five cancer cell lines. 
 
 
Scheme 6. Diphenylethylene–coumarin derivative synthesis. 
 
 
1.2. Pyranocoumarin derivatives 
Pyrano fused heterocyclic compounds (pyranocoumarins) are 
an important class of structural motif which posses a wide range 
of biological activity and are present in many natural products 
and synthetic drugs (Figure 2). They exhibit antifungal, 
insecticidal, anticancer, anti-HIV, anti-inflammatory and 
antibacterial activity. More specifically, pyrano[3,2-c]coumarins 
have become attractive synthetic targets for medicinal 
chemistry applications because of the broad spectrum of 
biological properties they display and relative natural 
abundance. 
 
 
Figure 2. Representative structures of pyrano[3,2-c]coumarin. 
 
The most common pyranocoumarin synthesis starts with the 
cyclization of 4-hydroxycoumarin (nucleophile) with 
electrophiles, such as α,β-unsaturated carbonyls (generally 
chalcones), 1,3-diarylallylic compounds, propargylic alcohols 
etc., while cyclohexane-1,3-diones are generally used as 
nucleophiles for benzopyran synthesis. Although some of these 
methods are efficient, most of them suffer from limitations, 
including long reaction times, expensive catalysts, strongly 
acidic and non-benign conditions, regioselectivity issues and 
poor yields. In view of their biological importance, Yaragorla et 
al. (2015),39 have developed a Ca(OTf)2 catalyzed, one-pot 
conjugate addition and annulation of various nucleophiles to 
the α,β−unsaturated carbonyl compounds for the synthesis of 
bioactive pyranocoumarins. The solvent-free reaction of 4-
hydroxycoumarin and chalcone with 5 mol % of Ca(OTf)2 and 
Bu4NPF6 (5 mol %) at 120 °C was performed on the gram scale. 
2,4-diphenylpyrano[3,2-c]chromen-5(4H)-one was obtained in 
a 92% yield (Scheme 7). As shown in scheme 8, the oxygen of 
the enone complexed Ca(II) and thus facilitated the conjugate 
addition (Michael type) of 4-hydroxycoumarin to intermediate 
I. In the second step, the oxyanion of Ca-enolate underwent 
intramolecular nucleophilic addition to intermediate (II). This 
was followed by Ca- catalyzed, thermodynamic annulation 
which delivered the final product. 
 
 
Scheme 7. Gram scale cascade, one-pot reaction of 4-hydroxycoumarin with chalcone 
for the synthesis of pyranocoumarins. 
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Scheme 8. Plausible mechanism for Ca(II)-catalyzed cascade conjugate addition and 
annulation in the synthesis of pyranocoumarins. 
Ashok et al. (2015),40 have synthesized hybrid pyranocoumarins 
in order to access the potential antimicrobial activity of 
coumarin scaffolds. The condensation of 8-acetyl-7-hydroxy-4-
methyl coumarin with aromatic or (het)aromatic aldehydes 
gave substituted (E)-1-(7-hydroxy-4-methyl-8-coumarinyl)-3-
(het)aryl-2-propen-1-ones in excellent yields in the presence of 
piperidine, under MW irradiation.41 The cyclization of these 
chalcones to  substituted 4-chloro-8-methyl-2-(het)aryl-1,5-
dioxa- 2H-phenanthren-6-ones was accomplished via treatment 
with the Vilsmeier- Haack reagent (POCl3-DMF). MW irradiation 
(160 W) gave excellent results (80-85% yield) in short reaction 
times (4–5 min) (Scheme 9). The antibacterial and antifungal 
activity of these novel compounds against Gram + (B. subtillis 
and S. aureus), and Gram- bacteria (Klebsiella pneumoniae and 
E. coli), as well as against Fusarium oxysporum, A. niger and A. 
flavus was evaluated. Compounds A, B and C showed significant 
action against the tested bacterial strains compared to the 
standard drug, gatifloxacin. 
 
 
Scheme 9. Synthesis of substituted 4-chloro-8-methyl-2-phenyl-1,5-dioxa-2H-
phenanthren-6-ones. 
The same compounds also showed moderate to high antifungal 
activity compared to the standard drug, clotrimazole. 
As stated earlier, coumarin derivatives are versatile molecules 
that can be transformed into new active heterocyclic products. 
In addition, sulfone groups that are strategically positioned in 
heterocyclic compounds can play important roles in drug 
design. Accordingly, pyrrolyl aryl sulfones (PASs) have been 
reported,42 as a new class of human immunodeficiency virus 
type 1 (HIV-1) RT inhibitors which act on the non-nucleoside 
binding site of this enzyme. Al-bogami (2015), 42 has made use 
of the sonochemistry concept for the rapid and efficient 
synthesis of some novel pyrano[3,2-c]coumarins which contain 
the sulfone moiety with the aim of synthesizing new 
heterocyclic compounds for biological screening. Each reaction 
of 4-hydroxy coumarin, aromatic aldehydes and 2-
(phenylsulfonyl)-acetonitrile in EtOH, in the presence of 
catalytic  piperidine under ultrasonic irradiation at room 
temperature, afforded a single product identified as  the 
corresponding 2-amino-3-phenylsulfonyl-4-aryl-4H-pyrano[3,2-
c]coumarin (Scheme 10), in excellent yields (88-94%) and 
shorter reaction times (30-45 min) than under conventional 
conditions (reflux) (74-79%, 10 h). 
 
 
Scheme 10. Synthesis of 2-amino-3-phenylsulfonyl-4aryl-4H pyrano [3,2-c]coumarin 
derivatives. 
In a similar procedure, β-ketosulfones were reacted 
uneventfully with 4-hydroxy coumarin and aromatic aldehyde 
derivatives under ultrasonic irradiation (room temperature, 45 
min) to provide 2,4-diaryl-3-(phenylsulfonyl)pyrano[3,2-
c]coumarin derivatives in virtually quantitative yields (Scheme 
11). 
 
 
Scheme 11. Synthesis of 2,4-diaryl-3-(phenylsulfonyl)pyrano[3,2-c]coumarin derivatives. 
1.3. Furocoumarin derivatives 
Furocoumarins are another structural motif found in numerous 
pharmaceutically active compounds. A number of excellent 
reviews43-47 exist on this subject. However, for the sake of 
brevity, we shall only deal with compounds that bear the 
furo[3,2-c]coumarin ring system in this review. Some of these 
molecules have successfully been used for the treatment of skin 
diseases, such as cancer and psoriasis. In particular, 
neotanshinlactone and coumestrol exhibit high anti-tumour 
tissue-type as well as anti-breast cancer cell line selectivity (Fig. 
3). For this reason, considerable effort has been invested in 
designing efficient synthetic methods of furocoumarin 
synthesis. The main features of a modern and straightforward 
furocoumarin synthetic protocol are: good atom-economy, mild 
conditions, low cost, green solvents and high regioselectivity. In 
this regard, Tan et al. (2015),48 have developed the successful 
Pd(CF3COO)2 catalyzed aerobic oxidative alkoxylation of 4-
hydroxycoumarins and alkenes in a cascade sequence to afford 
furo[3,2-c]coumarins in good yields (70-85%). 
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Figure 3. Furo[3,2-c]coumarins with high anti-tumour activity. 
 
The best reaction conditions were described as follows; 90 °C, 
20 mol% of Pd(CF3COO)2 catalyst and 1:1 (4-
hydroxycoumarin:alkenes) molar ratio. The desired products 
(Scheme 12) were obtained in 4 h in higher yields from electron-
rich than from electron-poor  alkenes. 
 
 
Scheme 12. Synthesis of substituted furo[3,2-c]coumarins from 4- hydroxycoumarins 
and alkenes. 
 
Zhang et al. (2014),49  described the fast, MW-assisted synthesis 
of new furo and benzofuro coumarins. In particular, furo[3,2-
c]chromen-4-one and 7,8,9,10-tetrahydro-6H-benzofuro[3,2-
c]chromen-6-one derivatives (30 min, 400 W) (Scheme 13) were 
obtained in relatively good  yields (50-65%) from 4-
hydroxycoumarin and a variety of a-chloroketones and a-
bromocyclohexanones. 
 
 
Scheme 13. Synthesis of polysubstituted furo[3,2-c]chromen-4-ones and 7,8,9,10-
tetrahydro-6H-benzofuro[3,2-c]chromen-6-ones. 
 
All of the reported furo and benzo furo coumarins were tested 
against Collecterichum capsica, Rhizoctorzia solani and Botrytis 
cinerea showing very good activity relative to osthol which was 
used as the reference fungicidal drug. Moreover, the antifungal 
data reveal that the coumarin C-7 substituents and the furano 
ring were the two major structural reasons for their antifungal 
bioactivity. 
 
1.4. Hybrid coumarin derivatives 
Combining two pharmacological agents into a single molecule, 
a hybrid molecule, is an emerging strategy in medicinal 
chemistry and drug discovery.50,51 Hybrid structures may display 
dual activity but do not necessarily act on the same biological 
target. Desai et al. (2013)52 have reported on the conventional 
and MW assisted syntheses of new coumarin-based 3-
cyanopyridine scaffolds [i.e. 3-(2-pyridyl)coumarins and 3-(3- 
pyridyl)coumarins], which bear a sulfonamide group, and have  
evaluated their antibacterial and antifungal properties. The 
coumarin nucleus in these compounds is attached at the C-3 
position by pyridine moieties and the second pyridine ring 
position has been linked with the phenyl ring by a sulphonamide 
group. The pyridine ring was de novo synthesized via a 4-
component  [2+2+1+1] reaction between 3-acetyl-6-fluoro-2H-
chromen-2-one 3, malononitrile, aromatic aldehydes  and 
ammonium acetate  to give 2-amino-6-(6-fluoro-2-oxo-2H-
chromen-3-yl)-4-(aryl) nicotinonitriles which were, in turn, N-
sulfonylated to the target compounds (Scheme 14). The MW 
assisted method was much more efficient and gave the best 
yields (66-82 %) in shorter reaction times (6-10 min). 
 
 
Scheme 14. Synthetic pathway. 
Furthermore, the new compounds were all tested for their 
antibacterial and antifungal activities against E. coli, S. aureus, 
P. aeruginosa, S. pyogenes, C. albicans, A. niger and A. clavatus. 
Compounds reported on Scheme 14 showed excellent activity. 
but others reported by Desai et al. had just moderate or weak  
activity. 
 The presence of indole rings in a number of bioactive 
compounds means that novel methods for the preparation of 
polyfunctionalized indole derivatives are of great interest. The 
combined use of a Lewis acid catalysis and MW irradiation 
provided Viola et al. (2014),53 with satisfactory results in the 
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Yonemitsu-type trimolecular condensation of indoles with 
aldehydes and 1,3-dicarbonyl compounds (malonates or 
acetoacetates), and yielded novel indole-coumarin compounds 
(Scheme 15). The main advantage of this procedure is the use 
of a catalytic amount of Lewis acid and the great reduction in 
reaction times (7 min), given by MW activation (250 W). The 
procedure was applied to aliphatic and aromatic aldehydes, as 
well as to substituted indoles. The optimization of the 
conditions for malonate and acetoacetate gave satisfactory 
results for both substrates, providing efficient access to a new 
class of indole-coumarin derivatives of potential biological 
interest. 
Fluorine-containing organic compounds have provided a long 
contribution to medicinal chemistry. The unique properties of 
fluorine mean that the incorporation of an atom or fluorinated 
group into drugs is often accompanied by higher binding 
affinity, enhanced metabolic stability and improved 
bioavailability, which can all critically influence both the 
pharmacodynamic and pharmacokinetic properties of drugs. 
 
 
Scheme 15. Yonemitsu-type trimolecular condensation for indole-coumarin synthesis. 
 
Encouraged by the reported bioactive significance of coumarin 
(in its interactions with numerous enzymes and receptors) and 
pyrimidine derivatives (anticancer properties) in combination 
with the fluorine moiety (enhancement of activity), Hosamani 
et al. (2015)54 integrated these subunits into a single structural 
frame. These hybrid compounds may well exhibit high 
anticancer activity as a result of the synergetic effect of the 
combined units. Efficient synthetic entry to 3-(2-(4-
fluorobenzyl)-6-(substituted phenyl) pyrimidin-4-yl)-2H-
chromen-2-one derivatives under MW irradiation from 
substituted-enone coumarin derivatives (synthesized via the 
Claisen–Schmidt condensation reaction) was described in this 
work. Their subsequent heterocyclization with 2-(4-
fluorophenyl) acetamidine hydrochloride in DMF afforded the 
desired 3-(2-(4-fluorobenzyl)-6- (substituted phenyl) pyrimidin-
4-yl)-2H-chromen-2-one derivatives (Scheme 16). 
Excellent yields were described in the presence of para or meta-
substituted chalconated coumarins, while lower yields were 
reported in the presence of the ortho substituted moieties, due 
to steric hindrance. 
 
Scheme 16. Synthesis of fluorinated coumarin–pyrimidine hybrids. 
Compound yields and reaction times were drastically improved 
under MW irradiation with respect to conventional methods 
(74-91%, 15-20 minutes). All fluorinated coumarin–pyrimidine 
hybrid compounds were screened for in vitro anti-cancer 
activity against two human cancer cell lines, A-549 (human lung 
carcinoma) and MDAMB-231 (human adenocarcinoma 
mammary gland), by MTT assay and were further evaluated for 
their CT-DNA cleavage using the agarose gel electrophoresis 
method. The results revealed that compounds (a) and (b) 
exhibit cytotoxicity against the two cancer cell lines tested 
which was comparable or longer than that of standard cisplatin. 
Tuberculosis (TB) is the world’s second leading cause of death 
by infectious disease, after acquired immune deficiency 
syndrome (AIDS), and as such, special effort is needed to find 
and develop new leads against the many validated TB targets.55 
The fact that coumarins have antitubercular properties while 
benzopyranopyrimidines show antifungal and antibacterial 
activity has lead to Ambre et al. (2014)56 formulated hypothesis 
that their fusion would bring synergism to the individual 
antitubercular activities. They then synthesized and tested 16 
new compounds that contained 4-(substituted)phenyl-1,2,3,4-
tetrahydro-benzopyrano [4,3-d]pyrimidine-2,5-dione, 4-
(substituted) phenyl-2-thioxo-1,2,3,4-tetrahydro-
benzopyrano[4,3-d]pyrimidin- 5-ones and 2-thiopyrimidone 
nuclei. The syntheses of these hybrid compounds were carried 
out via a 3-component Biginelli reaction which involved 
reactions between a substituted aldehyde, 6-substituted-4-
hydroxy coumarin and urea (or thiourea) in the presence of an 
acid catalyst (p-toluenesulfonic acid (PTSA)). The reaction was 
also successfully performed under MW irradiation (850 W, 2.5 
min, 90 % yields) in the absence of solvents (Scheme 17). 
The new structures were assayed against Mycobacterium 
tuberculosis using rifampicin as the standard. The described 
hybrid coumarin and pyrimidin-2,5-dione structures are divided 
into two classes according to their structures; 2-thioxo-5-one 
(class A) and 2,5-dione (class B) functionality. The majority of 
class A molecules are non-cytotoxic, as based on human virulent 
cell line evaluations, although they possess relatively good 
antitubercular activity. While the molecules of class B inhibit the 
growth of Mycobacterium tuberculosis, they have high 
cytotoxicity profiles. 
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Scheme 17. 3-Component Biginelli reaction for synthesis of hybrid coumarins which 
include pyrimidine with 2-thioxo-5-one (class A) and 2,5-dione (class B) functionality. 
Siddiqui and Khan (2014),57  have recently reported a solvent-
free, environmentally benign and simple one-pot multi-
component protocol for the synthesis of novel bis-Biginelli 
compounds (Fig. 4) in excellent yields using HClO4-modified 
PEG-6000 as a biodegradable and reusable solid acid catalyst at 
ambient temperature. 
 
 
Figure 4. Bis-Biginelli compound structure. 
Cyanopyridines and triazolopyridines have also played an 
important role as members of the wide variety of heterocycles 
in medicinal chemistry. Thakrar et al. (2014), 58  have reported 
the synthesis of 2-amino 3-cyano pyridine derivatives, which 
contain both coumarin and pyrazole moieties, via the 
multicomponent reaction of 3-acetyl 4-hydroxy coumarin, 1,3-
diphenyl-1H-pyrazole-4-carbaldehyde, malononitrile and 
ammonium acetate in the presence of acid catalysts under MW 
irradiation  (Scheme 18). 
 
 
Scheme 18. Synthetic pathway for 2-amino 3-cyano pyridine derivatives. 
 
Two solid acids, Fe(III) montmorillonite K10 clay and HY- 
zeolite were efficiently used as cheap, recyclable and easily-
available catalysts. The main advantages of this 
environmentally friendly procedure are the short reaction times 
(4-9 min), easy work up and good reaction yields.  
The newly synthesized 2-amino 3-cyano pyridine derivatives 
were screened for their antibacterial activity (vs. S. typhi, 
Streptococcus pyogenus and Vibrio cholera) and antifungal 
activity against C. albicans. 
A SAR study into these compounds has shown that EW-groups 
attached to coumarin rings increase potency (compounds (a), 
(b), (c), (d)), whereas hydrophobic groups lower potency against 
antibacterial species. All compounds exhibited less potency 
against C. albicans. In addition to the compounds mentioned 
above, pyrazole and isoxazole derivatives have also exhibited 
well documented biological properties (bacteriostatic, 
antidiabetic, anti-inflammatory, antimicrobial and anticancer 
properties) as have thiobarbituric acid (TBA) and barbituric acid 
(BA), which are generally used as sedatives and antibacterial, 
antidiabetic, antiviral and anticancer agents. In this regard, 
Laxmi et al. (2013),59 have reported the MW-assisted synthesis 
of a new class of pyrazole- barbiturate coumarin derivative and 
have assessed their antimicrobial activity. In particular, this 
series of 5-((3-(2-oxo-2H-chromen-3-yl)-1-phenyl-1H-pyrazol-4-
yl)methylene) pyrimidine-2,4,6(1H,3H,5H)-trione and dihydro-
5-((3-(2-oxo-2H-chromen-3-yl)-1-phenyl-1H-pyrazol-4-
yl)methylene)-2-thioxo pyrimidine-4,6(1H,5H)-dione 
derivatives were synthesized via the Knoevenagel condensation 
of 3-(2-oxo-2H-chromen-3-yl)-1-phenyl- 1H-pyrazole-4-
carbaldehyde with barbituric acid and thiobarbituric acid in 
acetic acid under MW irradiation, giving excellent yields (75-
85%) in shorter times (5-10 min) than conventional heating (5-
10 h) (Scheme 19). 
 
 
Scheme 19. Synthesis of pyrazole- barbiturate coumarin derivatives. 
 
The substituted 3-acetyl coumarins were treated with phenyl 
hydrazine in methanolic acetic acid under reflux (30 min) to 
afford the corresponding phenyl hydrazones that were 
subsequently transformed to the corresponding 1H-pyrazole-4-
carbaldehyde derivatives using the Vilsmeier formylation. The 
newly synthesized compounds were then evaluated for their 
antibacterial activity against B. subtilis, S. aureus, S. epidermidis, 
E. coli, P. aeruginosa and K. pneumoniae. All compounds were 
found to be moderately active against the microorganisms, 
while compounds (a) and (b) exhibited good antifungal activity 
against A. niger. 
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The antioxidant effects of coumarins have also attracted intense 
interest in recent years. These properties permit coumarins to 
quench active free radicals, such as O2•, OH• and lipid peroxyl 
radicals LOO•, while the core pyrazolone structure has generally 
been of interest because of its large range of activity. In view of 
these observations, Sivakumar et al. (2014),60 have reported the 
synthesis of Mannich base pyrazolone-coumarin derivatives, 
(using both conventional and eco-friendly dielectric heating), 
which have been found to possess interesting anti-
inflammatory and analgesic activity coupled with a significant 
reduction in their ulcerogenic potential. The synthetic pathway 
for these hybrid compounds is displayed below (Scheme 20). 
Ethyl 2-oxo-2H-chromene-3-carboxylate was prepared via the 
cyclization of salicylaldehyde with diethylmalonate in the 
presence of catalytic piperidine.61 The subsequent reaction with 
hydrazine hydrate, followed by heterocyclization with ethyl 
acetoacetate in glacial acetic acid, provided the corresponding 
pyrazolone. The condensation of pyrazolone with formaldehyde 
(40%) and various aromatic primary amines resulted in a set of 
Mannich bases. MW assisted techniques were found to be more 
effective in terms of impact on the environment, reaction time, 
high yields, ease of work-up and product isolation (78-88% vs 
55-69% yields).  
 
 
 
Scheme 20. Synthetic pathway for the Mannich base pyrazolone-coumarin derivatives.  
 
The newly synthesized compounds, which combined both 
pyrazolone–linked coumarins, were screened for anti-
inflammatory, analgesic, antioxidant and antibacterial activity 
and their effects were compared with those of standard drugs. 
Of the compounds studied, (a) displayed anti-inflammatory and 
analgesic activity which was nearly equipotent to the standard 
drug indomethacin, along with a minimal ulcerogenic index. The 
substitution of EW-groups at the para/ortho position of the 
phenyl ring imparted significant anti-inflammatory and 
analgesic activity to the resulting compounds. The compounds 
screened for their in vitro antimicrobial activity against Gram-
positive (Micrococcus luteus, S. aureus) and Gram-negative 
bacteria (E. coli and K. pneumoniae) displayed better activity 
(especially in the presence of electron donating  (ED)  groups at 
the para position in the Mannich base phenyl ring) against 
Gram-negative than against Gram-positive bacteria. However, 
starting from this positive finding all the other compounds 
demonstrated weak to moderate activity compared to 
ciprofloxacin. 
It has been well established that the presence of the 7-hydroxy-
4-methyl-2-coumarin moiety is an important structural feature 
of a wide variety of synthetic drugs. The additional presence of 
heterocyclic moieties such as 1,3,4-triazole, -thiadiazole and -
oxadiazole further extend this wide range of therapeutic 
properties. As a result, the preparation of novel compounds 
that fuse these azoles onto a coumarin structure has been 
reported by Surendra Babu et al. (2014).62 In this procedure, the 
key intermediate, ethyl-2-(4-methyl-2-oxo-2-coumarin-7-
yloxy)acetate, was prepared via the reaction of 7-hydroxy-4-
methyl coumarin in the presence of anhydrous K2CO3 with ethyl 
chloroacetate in boiling acetone. This compound was readily 
converted to 2-(4-methyl-2-oxo-2H-chromen-4-
yloxy)acetohydrazide via treatment with hydrazine hydrate. 
The resulting hydrazide was reacted with substituted aryl 
isothiocyanates to form thiosemicarbazide compounds. The 1-
(2-(4-methyl-2-oxo-2-coumarin-7-yloxy)acetyl)-4-aryl 
thiosemicarbazides underwent cyclization with different 
reagents under conventional, MW and grinding conditions to 
furnish coumarin derivatives that bore triazoles (in the presence 
of NaOH), thiadiazoles (in the presence of conc. H2SO4.), and 
oxadiazoles (in the presence of NaOH/KI3), respectively 
(Scheme 21). 
 
 
 
Scheme 21. Triazole, oxadiazole, thiadiazole-coumarin hybrid structures. 
In this case, MW- and grinding-assisted procedures provided 
advantages in terms of reaction time and yields. The MW 
irradiation method, in particular, gave products in less time and 
better yields (2-3 min, 70–85%). The synthesized compounds 
were screened for their antibacterial activities against K. 
pneumonia and E. coli bacterial strains and antifungal activity 
against A. niger, A. fumigates and A. terreus. All compounds 
showed moderate to good activity against all the tested 
organisms. 
With an eye to the relevance of both quinoline (antimalarial, 
anti-inflammatory, antiasthmatic, antibacterial, 
antihypertensive and anticancer activity) and coumarin as 
pharmacophoric units,  Balaji et al. (2013),63 have reported the 
synthesis of 7-(2-chloroquinolin-4-yloxy)-4-methyl-2H-
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chromen-2-one derivatives and their in vitro antibacterial, 
antioxidant and molecular docking studies. Quinoline-based 
coumarin derivatives were synthesized via the one-pot 
alkylation of 2,4-dichloroquinolines with 7-hydroxy-4-methyl-
2H-chromen-2-one in the presence of catalytic amounts of 
K2CO3 under ultrasonic irradiation (60 °C, 20 min) (Scheme 22). 
 
 
 
Scheme 22. Synthesis of 7-(2-chloroquinolin-4-yloxy)-4-methyl-2H-chromen-2-one 
derivatives.  
While the observed reactivity of the halogen atoms in the 
various quinolines varied widely, kinetic studies underlined the 
fact that the chlorine atom on the C-4 of 2,4-dichloroquinolines 
showed doubled reactivity towards nucleophilic reactions 
(making this a highly regioselective procedure), which 
predominantly take place via a σX complex in an addition-
elimination mechanism. All synthesized compounds were 
screened for antibacterial (E. coli, P. aeruginosa, S. aureus, and 
B. subtilis) and antioxidant activities. Some of these quinoline- 
based coumarin hybrids were found to be equipotent or even 
more potent than the standard drug, streptomycin. 
Multicomponent reactions (MCRs) have proven themselves to 
be valuable tools in medicinal chemistry and drug design 
because of their simplicity, efficiency and high selectivity. Such 
processes have the advantages of intrinsic atom economy, time 
and energy savings, as well as significant environmental 
benignity. In this regard, Chen et al. (2013)64 have reported the 
synthesis of 7,12-dihydro-6H-chromeno[4,3-b]quinolone 
derivatives via a three-component condensation of 4-
hydroxycoumarin with different aldehydes and aromatic 
amines in water. The best results (80-94 % yields) were 
described under MW irradiation (150 °C, 15-20 min), and using 
a sulfonic acidic ionic liquid [L-2-(hydroxymethyl)-1-(4-
sulfobutyl)pyrrolidinium hydrogen sulfate] ([HYSBPI].HSO4) as 
catalyst, which enhanced reactant water solubility (Scheme 23). 
The dimeric product, obtained together with 7,12-dihydro-6H-
chromeno [4,3-b] quinoline, is not unexpected as the reaction 
of 4-hydroxycoumarin with aldehydes is fully regio-and 
chemoselective, affording 3,3'-alkylidene-4,4-dihydroxybis [2H-
1-benzopyran-2-ones].65 
Since chromeno[4,3-b]quinolone derivatives showed moderate 
cytotoxic capacity and very low calcium channel antagonist 
activity, the antitumor activities of all the synthesized 
compounds were assessed on two different human cancer cell 
lines (A-549 and MCF-7). The results showed that these 
compounds had weak-to-good antitumor activities. 
 
 
 
Scheme 23. Synthesis of 7,12-dihydro-6H-chromeno[4,3-b]quinoline derivatives. 
Shivashankar et al. (2013),66 have optimized a simple protocol 
which produced a new class of dihydrobenzo[4,5]imidazo [1,2-
a]pyrimidin-4-one substituted coumarin using MW irradiation 
in an effort to discover novel antimicrobial and anticancer 
agents. In this procedure, the dihydrobenzo[4,5]imidazo[1,2-
a]pyrimidin-4-ones were first obtained in short reaction times 
and excellent yields (74-94%) via β-keto ester and 2-
aminobenzimidazole condensation under MW irradiation. 
These molecules were then reacted with various substituted 4-
bromomethylcoumarins (synthesized via the von Pechmann 
cyclization of phenols with 4-bromoethylacetoacetate in the 
presence of conc. H2SO4., used as a cyclizing agent) to yield this 
new series of substituted coumarins (Scheme 24). All the newly 
synthesized compounds were screened for their antibacterial 
and antifungal activity giving better antifungal than 
antibacterial properties. The in vitro cell cytotoxicity of these 
new coumarin substituted dihydrobenzo[4,5]imidazo [1,2-
a]pyrimidin-4-ones was also determined and the (a) structure 
was found to be the most potent cytotoxic compound (88%) 
against Dalton’s ascitic lymphoma cell line. 
 
 
Scheme 24. Dihydrobenzo[4,5]imidazo [1,2-a]pyrimidin-4-one substituted coumarin 
synthesis. 
It is now well known that chromene derivatives exhibit a wide 
range of biological activity, including antimicrobial, antioxidant, 
and antitumor properties. Rao et al. (2015),67 have therefore 
reported an eco-friendly and catalyst-free synthesis of novel 
hybrid chromene - coumarin derivatives (Scheme 25). The 
pivotal C–C bond formation was carried out in aqueous medium 
under MW irradiation, providing high conversion and high 
regio-selectivity in a short reaction time. A number of solvents 
were tested, but “in water” reactions were the most effective 
in terms of time and yields (78%, 105 °C). 
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Scheme 25. Synthesis of novel hybrid chromene - coumarin derivatives. 
The chemical and physical properties of water are altered at 
high temperatures under MW irradiation in such a way that it 
behaves both as a pseudo organic solvent and a phase transfer 
catalyst. Moreover, chromenes bearing EW substituents (-NO2, 
6,8 di-halogen) gave hybrid products in excellent yields, while 
ED-bearing moieties (-OMe) did not. All of the newly 
synthesized scaffolds were screened for their in vitro 
antimicrobial activity against the bacterial strains S. aureus, S. 
epidermidis, B. subtilis (Gram-positive organisms), E. coli, P. 
aeruginosa, K. pneumonia, (Gram-negative organisms) using 
the agar well diffusion method with penicillin and streptomycin 
as reference drugs. The experimental results indicated a 
variable degree of efficacy in all tested compounds. 
The versatile, medicinal and chemical properties of benzofuran 
and its derivatives have attracted considerable interest over 
recent years. Puttaraju et al. (2014),68 have therefore reported 
the synthesis of novel 4-(3-hydroxy-benzofuran-2-yl)coumarins 
and have evaluated them for their potential biological activity. 
Starting 4-bromomethylcoumarins were first obtained via the 
von Pechmann cyclization; 4-(6-methyl-2-oxo-2H-chromen-4-
ylmethoxy)-benzoic acid methyl ester was synthesized by 
reacting 4-bromomethyl-6-methylcoumarin and methyl 
salicylate in the presence of anhydrous K2CO3. These 
intermediates did not yield benzofuranyl coumarins in the 
presence of DBU and DMF under conventional thermal 
conditions (benzofuran cyclization does not occur), but only 
under MW irradiation (Scheme 26). 
 
 
Scheme 26. Benzofuranyl coumarin synthetic pathway. 
All compounds were tested for their antimicrobial activity and 
cytotoxicity in vitro. Uncyclized compounds (a) are generally 
more potent against S. mutans and E. coli than cyclized 
compounds (b), whereas cyclized compounds (b) are more 
potent against Enterococcus faecalis and C. albicans than the 
uncyclized analogues (a). Moreover, both cyclized and 
uncyclized compounds showed better activity against S. aureus 
than standard ciprofloxacin. Compound (b) (R = 6-OMe) was 
found to be more potently cytotoxic than standard 5-
fluorouracil. 
Nucleosides and modified nucleosides are another significant 
class of bioactive compound that can boast of very interesting 
biological activity, including antiviral, antimetabolic and 
anticancer properties. This has lead to Kallitsakis et al. (2013),69 
describing a new series of modified nucleosides, which combine 
coumarin and purine moieties to act as free-radical scavengers 
(Scheme 27). Coumarin-skeleton-modified acyclic purine N-
nucleosides were obtained via the cross metathesis (CM) 
reaction of 9-butenylpurines with 4-butenyloxycoumarins (a) 
and 4-allyloxycoumarins (b) in the presence of Grubbs 2nd 
generation catalyst under MW irradiation (100 °C, 3h). They 
were obtained in moderate to high yields (50-86%) without 
producing purine homodimers. Analogous derivatives obtained 
from the CM reaction of 9-butenyl-6-piperidinylpurine with 6-
coumarinyl acrylate were also described (c). These compounds 
were tested as possible lipoxygenase (LOX) inhibitors, hydroxyl 
radical (HO•) scavengers and potential inhibitors of lipid 
peroxidation and thrombin. Significant antioxidant activity was 
observed mostly in (a), (b) and (c), while only (b) and (c) showed 
any noteworthy interaction with the stable free-radical 
molecule 2,2-diphenyl-1-picrylhydrazyl (DPPH) and high 
scavenging  potency against HO• radicals. 
 
 
Scheme 27. Purine homo-N-nucleosides modified with coumarins. 
A recent report into the antibacterial properties of antibiotic-
amino acid conjugates has lead to a further development in 
bioconjugates as Tiwari et al. (2014),70 have reported novel 
synthetic conjugates of quinolone antibiotics that are linked to 
fluorescent coumarins by amino acid residues. Coumarins, well 
known for their antioxidant and antibiotic properties, also 
provide a large class of fluorescent laser dyes in the blue-green 
region. 
Substituted (coumarin-3-yl carbonyl)benzotriazoles were 
prepared via the reaction of the corresponding carboxylic acids, 
(1H-benzotriazole (BtH), thionyl chloride CH2Cl2, r.t.) and were 
subsequently coupled with amino acids in the presence of  TEA 
at r.t  to give  the required amino acid conjugates. These 
reactive intermediates were coupled with quinolone antibiotics 
using the same methodology (TEA, 70 °C, under MW irradiation) 
to give the target compounds in good yields (65-78%) (Scheme 
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28). These reactions were also carried out under conventional 
heating. 
 
 
Scheme 28. Quinolone antibiotics linked by amino acid residues to fluorescent 
coumarins. 
However, the reactions did not complete even after a number 
of hours. The photophysical properties of all the fluorescent-
labelled antibiotic conjugates synthesized were also 
investigated. Encouraged by the biological importance of 
coumarins, chalcones and triazoles, Dongamanti et al. (2014),71 
have described the efficient, practical and high-yielding MW-
assisted synthesis of a new series of hybrid coumarin-based 
compounds which contain both 1,2,3-triazole and chalcone. The 
synthesis of the desired product was accomplished using two 
synthetic strategies which are both shown in scheme 29. MW 
furnished shorter reaction times (5-10 min vs 24 h) and higher 
yields than under conventional conditions in both routes.  
All compounds were investigated for their in vitro antimicrobial 
activity against Gram -positive and -negative bacteria as well as 
fungi. The reported compounds ((a), (b), (c), (d) and (e)) showed 
good antimicrobial activity against selected microorganisms (S. 
aureus, B. subtilis, E. coli, P. aeruginosa) and fungi (A. niger, 
Penicillium italicum) as compared with reference drugs 
(amoxicillin and mycostatin). 
Finally, coumarin derivatives are also versatile synthons for the 
synthesis of a different set of rearranged products and new 
heterocyclic systems. Key 3-(2-oxo-2H-chromen-3-yl)-2-oxo-
2H,5H-pyrano[3,2-c]chromen-5-yl acetates have been 
synthesized in high yields (72-87%) via the cyclocondensation of 
4-oxo-4H-chromen-3-carbaldehydes  with coumarin-3-acetic 
acids under MW irradiation (10 min at 400 W) by Gašparová et 
al. (2013).72  
The reaction pathway (Scheme 30) involves aldol condensation 
and subsequent intramolecular lactonization to afford the 2-
oxo-2H,5H-pyrano[3,2-c]chromene skeleton. Further treatment 
of 3-(2-oxo-2H-chromen-3-yl)-2-oxo-2H,5H-pyrano[3,2-
c]chromen-5-yl acetates with alcohols, water or nitrogen 
containing compounds led to 5-alkoxy-, 5-hydroxy-or 5-
acylamino-2H,5H-pyrano[3,2-c]chromen-2-ones via the 
nucleophilic substitution of acetoxy group at C-5.  
 
 
Scheme 29. Hybrid coumarin-based compounds containing both 1,2,3-triazole and 
chalcone. 
 
Scheme 30. Synthesis of 5-alkoxy-, 5-hydroxy-or 5-acylamino-2H,5H-pyrano[3,2-
c]chromen-2-ones. 
Acetates and hydroxyl derivatives undergo facile 
rearrangement in an acid medium to yield 5-
hydroxypyrano[2,3-b]chromen-2(10aH)-ones (Scheme 31). 
 
 
 
Scheme 31. Rearrangement to 5-hydroxypyrano[2,3-b]chromen-2(10aH)-ones. 
The antineoplastic activities of twelve prepared compounds 
were evaluated on 60 human tumour cell lines. The results 
confirmed the role of 3-(2-oxo-2H-chromen-3-yl)-2H,5H-
pyrano[3,2-c]chromen-2-one as a new leading skeleton and one 
which is worthy of further antitumor activity study. 
2 Conclusion 
The synthesis of coumarins and their derivatives has drawn the 
attention of organic and medicinal chemists over the decades. 
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Recent years have seen a greener approach being taken while 
the use of MW-assisted enabling technologies, sonochemical 
conditions and heterogeneous catalysis have made access to 
these heterocyclic compounds much simpler. This review 
summarizes the most recent advances in the synthesis of 
bioactive coumarins and some perspectives in the application 
of non-conventional methods and energy sources. 
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